- 期刊
Trends of Treatments of Hepatocellular Carcinoma in Recent 3-Decade Based on the Top-100 Influential Articles from Taiwan
摘要
Objective: The prevalence of liver cancer is still high in Taiwan and remained flat epidemiological curve in recent decades despite improvements in hepatitis and cancer surveillance programs. Therefore, we designed this study using bibliometric citation analysis to outline the trends of treatments of hepatocellular carcinoma (HCC) patients in Taiwan. Methods: The Web of Science Core Collection Database searched interrelated articles published from 1992 to 2021, and divided into 1^(st), 2^(nd), and 3^(rd) decades. Taiwan Top-100 articles were selected based on the yearly highest-ranking cited times and limited in the studies of treatment. Results: Total of 38,838 articles on clinical studies of liver cancer were observed in our search. The top numbers of articles from the Top-10 countries were analyzed in which China ranked the first, followed by the United States of America, and Japan among 144 countries. Moreover, 1,833 (4.72%) articles published from Taiwan ranking as the 9^(th) in the world. The contributions of these 1,833 articles were reported by 202 institutions of Taiwan. The numbers of articles were published 127 (6.9%), 461 (25.2%) and 1,245 (67.9%) in the 1^(st), 2^(nd) and 3^(rd) decades respectively. Taiwan Top-100 articles were averagely selected and limited in treating patients with hepatocellular carcinoma. The treatment methods were found 66.7% with hepatic resection and 33.3% with transhepatic artery chemo-embolization in 1992-2001. After 2002, multiple treatment methods could be applied, including target therapy and immune cell therapy. Publications concerning hepatectomy decreased in publications from 66.7%, 25.7% to 13.5% in the periods of 1992-2001, 2002-2011, and 2012-2021 respectively. In contrary, target and immunotherapy were markedly increased with 29.7% and 18.9% among all treatment methods in 2012-2021. Conclusions: Clinical studies were actively conducted in Taiwan because of the burden of liver diseases. Surgical resection and regional ablation were the main in the 1^(st) and 2^(nd) decades and decreased in publications gradually. Molecular targeted agent therapy and immunotherapy were sprung into a half territory of publications concerning the clinical treatment of HCC after 2012 in Taiwan.